Do Rheumatoid Arthritis Patients in clinical practice benefit from switching from Infliximab to a second tumor necrosis factor alpha inhibitor?

E Hjardem; M. Østergaard; J. Pødenphant; U. Tarp; L. Smedegaard Andersen; J. Bing; Elisabeth Peen

Do Rheumatoid Arthritis Patients in clinical practice benefit from switching from Infliximab to a second tumor necrosis factor alpha inhibitor?

E Hjardem, M. Østergaard, J. Pødenphant, U. Tarp, L. Smedegaard Andersen, J. Bing, Elisabeth Peen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	66
Udgave nummer	9
Sider (fra-til)	1184
ISSN	0003-4967
Status	Udgivet - 2007

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

@article{3ed36de0ca6a11dc8dd8000ea68e967b,

title = "Do Rheumatoid Arthritis Patients in clinical practice benefit from switching from Infliximab to a second tumor necrosis factor alpha inhibitor?",

author = "E Hjardem and M. {\O}stergaard and J. P{\o}denphant and U. Tarp and {Smedegaard Andersen}, L. and J. Bing and Elisabeth Peen",

year = "2007",

language = "English",

volume = "66",

pages = "1184",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",